EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access

Progression of Vascular Calcification and Clinical Outcomes in Patients Receiving Maintenance Dialysis

Haitao Zhang, Guisen Li, Xueqing Yu, Junwei Yang, Aili Jiang, Hong Cheng, Junzhou Fu, Xinling Liang, Jun Liu, Jizhuang Lou, Mei Wang, Changying Xing und 17 weitere

JAMA Network Open · 01.05.2023 · 6 (5) · e2310909

DOI: 10.1001/jamanetworkopen.2023.10909 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift JAMA Network Open, online erschienen am 01.05.2023. Verfasst von Haitao Zhang und 28 weiteren Autor:innen. Beteiligte Einrichtung: National Clinical Research Center of Kidney Diseases, Jinling Hospital, Nanjing University School of Medicine, Nanjing, China. Hauptthemen laut MEDLINE: Renal Dialysis, Vascular Calcification. Die Arbeit wurde bisher 117-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Baseline findings from the China Dialysis Calcification Study (CDCS) revealed a high prevalence of vascular calcification (VC) among patients with end-stage kidney disease; however, data on VC progression were limited.

Objectives

To understand the progression of VC at different anatomical sites, identify risk factors for VC progression, and assess the association of VC progression with the risk of cardiovascular events and death among patients receiving maintenance dialysis. Design, Setting, and Participants This cohort study was a 4-year follow-up assessment of participants in the CDCS, a nationwide multicenter prospective cohort study involving patients aged 18 to 74 years who were undergoing hemodialysis or peritoneal dialysis. Participants were recruited from 24 centers across China between May 1, 2014, and April 30, 2015, and followed up for 4 years. A total of 1489 patients receiving maintenance dialysis were included in the current analysis. Data were analyzed from September 1 to December 31, 2021. Exposures Patient demographic characteristics and medical history; high-sensitivity C-reactive protein laboratory values; serum calcium, phosphorus, and intact parathyroid hormone (iPTH) values; and previous or concomitant use of medications. Main Outcomes and Measures The primary outcome was progression of VC at 3 different anatomical sites (coronary artery, abdominal aorta, and cardiac valves) and identification of risk factors for VC progression. Participants received assessments of coronary artery calcification (CAC), abdominal aortic calcification (AAC), and cardiac valve calcification (CVC) at baseline, 24 months, 36 months, and 48 months. Secondary outcomes included (1) the association between VC progression and the risk of all-cause death, cardiovascular (CV)–related death, and a composite of all-cause death and nonfatal CV events and (2) the association between achievement of serum calcium, phosphorus, and iPTH target levels and the risk of VC progression.

Results

Among 1489 patients, the median (IQR) age was 51.0 (41.0-60.0) years; 59.5% of patients were male. By the end of 4-year follow-up, progression of total VC was observed in 86.5% of patients; 69.6% of patients had CAC progression, 72.4% had AAC progression, and 33.4% had CVC progression. Common risk factors for VC progression at the 3 different anatomical sites were older age and higher fibroblast growth factor 23 levels. Progression of CAC was associated with a higher risk of all-cause death (model 1 [adjusted for age, sex, and body mass index]: hazard ratio [HR], 1.97 [95% CI, 1.16-3.33]; model 2 [adjusted for all factors in model 1 plus smoking status, history of diabetes, and mean arterial pressure]: HR, 1.89 [95% CI, 1.11-3.21]; model 3 [adjusted for all factors in model 2 plus calcium, phosphorus, intact parathyroid hormone, and fibroblast growth factor 23 levels and calcium-based phosphate binder use]: HR, 1.92 [95% CI, 1.11-3.31]) and the composite of all-cause death and nonfatal CV events (model 1: HR, 1.98 [95% CI, 1.19-3.31]; model 2: HR, 1.91 [95% CI, 1.14-3.21]; model 3: HR, 1.95 [95% CI, 1.14-3.33]) after adjusting for all confounding factors except the presence of baseline calcification. Among the 3 targets of calcium, phosphorus, and iPTH, patients who achieved no target levels (model 1: odds ratio [OR], 4.75 [95% CI, 2.65-8.52]; model 2: OR, 4.81 [95% CI, 2.67-8.66]; model 3 [for this analysis, adjusted for all factors in model 2 plus fibroblast growth factor 23 level and calcium-based phosphate binder use]: OR, 2.76 [95% CI, 1.48-5.16]), 1 target level (model 1: OR, 3.71 [95% CI, 2.35-5.88]; model 2: OR, 3.62 [95% CI, 2.26-5.78]; model 3: OR, 2.19 [95% CI, 1.33-3.61]), or 2 target levels (model 1: OR, 2.73 [95% CI, 1.74-4.26]; model 2: OR, 2.69 [95% CI, 1.71-4.25]; model 3: OR, 1.72 [95% CI, 1.06-2.79]) had higher odds of CAC progression compared with patients who achieved all 3 target levels. Conclusions and Relevance In this study, VC progressed rapidly in patients undergoing dialysis, with different VC types associated with different rates of prevalence and progression. Consistent achievement of serum calcium, phosphorus, and iPTH target levels was associated with a lower risk of CAC progression. These results may be useful for increasing patient awareness and developing appropriate strategies to improve the management of chronic kidney disease–mineral and bone disorder among patients undergoing dialysis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Renal DialysisVascular CalcificationHumansMaleFemaleFibroblast Growth Factor-23Cohort StudiesCalciumProspective StudiesRisk FactorsParathyroid HormonePhosphatesPhosphorus

Substanzen

Fibroblast Growth Factor-23CalciumParathyroid HormonePhosphatesPhosphorus

Autor:innen und Institutionen

  • National Clinical Research Center of Kidney Diseases, Jinling Hospital, Nanjing University School of Medicine, Nanjing, China.
  • Department of Nephrology, Sichuan Provincial People's Hospital, Chengdu, China.
  • Division of Nephrology, Guangdong Provincial People's Hospital, Guangzhou, China.
  • Center of Kidney Disease, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, China.
  • Department of Kidney Diseases and Blood Purification, The Second Hospital of Tianjin Medical University, Tianjin, China.
  • Nephrology Department, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.

Zitieren

APA

Zhang, H., Li, G., Yu, X., Yang, J., Jiang, A., Cheng, H., Fu, J., Liang, X., Liu, J., Lou, J., Wang, M., Xing, C., Zhang, A., Zhang, M., Xiao, X., Yu, C., Wang, R., Wang, L., Chen, Y., …, & China Dialysis Calcification Study Group (2023). Progression of Vascular Calcification and Clinical Outcomes in Patients Receiving Maintenance Dialysis. JAMA Network Open, 6(5), e2310909. https://doi.org/10.1001/jamanetworkopen.2023.10909

Vancouver

Zhang H, Li G, Yu X, Yang J, Jiang A, Cheng H, et al. Progression of Vascular Calcification and Clinical Outcomes in Patients Receiving Maintenance Dialysis. JAMA Network Open. 2023;6(5):e2310909. doi:10.1001/jamanetworkopen.2023.10909

BibTeX
@article{Zhang2023,
  author = {Zhang, Haitao and Li, Guisen and Yu, Xueqing and Yang, Junwei and Jiang, Aili and Cheng, Hong and Fu, Junzhou and Liang, Xinling and Liu, Jun and Lou, Jizhuang and Wang, Mei and Xing, Changying and Zhang, Aihua and Zhang, Miao and Xiao, Xiangcheng and Yu, Chen and Wang, Rong and Wang, Li and Chen, Yuqing and Guan, Tianjun and Peng, Ai and Chen, Nan and Hao, Chuanming and Liu, Bicheng and Wang, Suxia and Shen, Dan and Jia, Zhenhua and Liu, Zhihong and China Dialysis Calcification Study Group, China Dialysis Calcification Study Group},
  title = {Progression of Vascular Calcification and Clinical Outcomes in Patients Receiving Maintenance Dialysis},
  journal = {JAMA Network Open},
  year = {2023},
  volume = {6},
  number = {5},
  pages = {e2310909},
  doi = {10.1001/jamanetworkopen.2023.10909}
}
Kostenlos starten →